Novel targeted drugs for the treatment of multiple myeloma: From bench to bedside

Leukemia

Volumn 19, Issue 10, 2005, Pages 1729-1738

  Bruno, Benedetto ^a   Giaccone, L ^a   Rotta, M ^a   Anderson, K ^b   Boccadoro, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Multiple myeloma; New drugs; Signaling pathways

Indexed keywords

3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; CELL PROTEIN; CHIR 258; DEHYDRODIDEMNIN B; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR; GW 654652; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NVP AEW541; NVP LBH589; PEPTIDE DERIVATIVE; PRO 001; PROTEIN KINASE INHIBITOR; REGULATOR PROTEIN; SMALL INTERFERING RNA; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; VORINOSTAT;

ACUTE KIDNEY FAILURE; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE DISEASE; BONE MARROW; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CELL INTERACTION; CELL MATURATION; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; HUMAN; INJECTION PAIN; INJECTION SITE REACTION; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG EMBOLISM; MICROENVIRONMENT; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYELOMA CELL; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHLEBITIS; PLASMA CELL; PLASMACYTOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDATION; SIGNAL TRANSDUCTION; SOMNOLENCE; SURVIVAL TIME; TUMOR CELL; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 27144502081     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403905     Document Type: Review

References (58)

1. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998; 104: 439-444.
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
3. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
4. Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A et al. New drugs for reatment of multiple myeloma. Lancet Oncol 2004; 5: 430-442.
5. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
6. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002; 168: 2544-2553.
7. Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci USA 1998; 95: 11107-11112.
8. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212-2221.
9. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991-6000.
10. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428-435.
11. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
12. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 2001; 20 4519-4527.
13. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002; 21: 5673-5683.
14. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D et al. The biological sequelae of stromal cell-derived factor-1 alpha in multiple myeloma. Mol Cancer Ther 2002; 1: 539-544.
15. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000; 111: 626-634.
16. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000; 60: 6763-6770.
17. Qiang Yw, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: Downstream elements, functional correlates, and pathway cross-talk. Blood 2002; 99: 4138-4146.
18. Ge NI, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856-2861.
19. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002; 62: 3876-3882.
20. Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: Study in the 5T33MM model. Br J Cancer 2004; 90: 1076-1083.
21. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-239.
22. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004; 64: 1546-1558.
23. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941-2948.
24. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-4062.
25. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 18: 1565-1571.
26. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
27. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897-901.
28. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, et al., Polish Multiple Myeloma Study Group. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404-408.
29. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377-3382.
30. Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87 408-414.
31. Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: Adverse prognostic impact of advanced age. Blood 2003; 102: 69-77.
32. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399-403.
33. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-995.
34. Kropff MH, Lang N, Bisping G, Domine N, Innig G, Hentrich M et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607-616.
35. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J et al. DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732-2739.
36. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274-1276.
37. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
38. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
39. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
40. Palumbo A, Bertola A, Musto P, Pregno P, Bringhen S, Rus C et al. Oral melphalan, prednisone and thalidomide for multiple myeloma. Cancer, in press.
41. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
42. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98 1614-1615.
43. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 2002; 100: 1168-1171.
44. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
45. Richardson P. Clinical update: Proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003; 29 (Suppl 1): 33-39.
46. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
47. Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005; 29: 587-590.
48. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al. PAD combination therapy (PS-341/bortezomid, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 725-762.
49. Jagannath S, Durie BGM, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomid therapy alone and in combination with dexamethasone for patients with previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 7764-7783.
50. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992; 340: 1049-1052.
51. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005; 19: 664-670.
52. Berenson J. Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients - the American experience. Br J Clin Pract Suppl 1996; 87: 5-7.
53. Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003; 102: 2345-2350.
54. Borad MJ, Swift R, Berenson JR. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 2005; 19: 154-156.
55. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004; 104: 3712-3721.
56. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19: 1248-1252.
57. Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 2003; 4: 284-292.
58. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: Lessons from the 5TMM models. Immunol Rev 2003; 194 196-206.